{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:02:40Z","timestamp":1789437760993,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["HORIZON-MSCA-2023-SE-01"],"award-info":[{"award-number":["HORIZON-MSCA-2023-SE-01"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008425","name":"Government of Galicia Department of Education Science Universities and Professional Training","doi-asserted-by":"publisher","award":["GRC2022\/039"],"award-info":[{"award-number":["GRC2022\/039"]}],"id":[{"id":"10.13039\/501100008425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018703","name":"European Innovation Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PID2021-122335NB-I00"],"award-info":[{"award-number":["PID2021-122335NB-I00"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["MCIN\/AEI\/10.13039\/50110-0011033"],"award-info":[{"award-number":["MCIN\/AEI\/10.13039\/50110-0011033"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["FIS20\/00310"],"award-info":[{"award-number":["FIS20\/00310"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["EVEREST-101183034"],"award-info":[{"award-number":["EVEREST-101183034"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2022-137027OB-I00"],"award-info":[{"award-number":["PID2022-137027OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["MICIU\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["MICIU\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2022-137027OB-I00 ERDF\/EU"],"award-info":[{"award-number":["PID2022-137027OB-I00 ERDF\/EU"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["EVEREST- 101183034"],"award-info":[{"award-number":["EVEREST- 101183034"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2026.201129","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:58:54Z","timestamp":1768377534000},"page":"201129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pyrimidine-based compounds as promising anticancer agents targeting tumor cell senescence"],"prefix":"10.1016","volume":"34","author":[{"given":"Paula","family":"Carpintero-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Montserrat","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Carneiro-Figueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Garc\u00eda-Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Barturen-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"P\u00e9rez-Caaveiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Guiti\u00e1n-Caama\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Sarandeses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 P\u00e9rez","family":"Sestelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda D.","family":"May\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201129_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omton.2026.201129_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41523-025-00835-7","article-title":"Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021","volume":"11","author":"Thomas","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.omton.2026.201129_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201129_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000446","article-title":"Precision oncology: separating the wheat from the chaff","volume":"3","author":"Remon","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.omton.2026.201129_bib5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201129_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.omton.2026.201129_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201129_bib8","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201129_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100646","article-title":"The emergence of drug resistance to targeted cancer therapies: Clinical evidence","volume":"47","author":"Sarmento-Ribeiro","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.omton.2026.201129_bib10","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/s41467-020-16212-w","article-title":"Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures","volume":"11","author":"Vander Velde","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201129_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.omton.2026.201129_bib12","doi-asserted-by":"crossref","first-page":"16852","DOI":"10.3390\/molecules200916852","article-title":"Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine's Tool Box","volume":"20","author":"Martins","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.omton.2026.201129_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115101","article-title":"Triazole-fused pyrimidines in target-based anticancer drug discovery","volume":"249","author":"Dai","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.omton.2026.201129_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ph17101258","article-title":"Pyrimidines: A New Versatile Molecule in the Drug Development Field, Scope, and Future Aspects","volume":"17","author":"Venugopala","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omton.2026.201129_bib15","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.bmc.2018.03.024","article-title":"Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors","volume":"26","author":"Cui","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.omton.2026.201129_bib16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1021\/ml200156t","article-title":"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer","volume":"2","author":"Burger","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.omton.2026.201129_bib17","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm9911332","article-title":"Application of similarity matrices and genetic neural networks in quantitative structure-activity relationships of 2- or 4-(4-Methylpiperazino)pyrimidines: 5-HT(2A) receptor antagonists","volume":"43","author":"Borowski","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omton.2026.201129_bib18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrm3823","article-title":"Cellular senescence: from physiology to pathology","volume":"15","author":"Mu\u00f1oz-Esp\u00edn","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201129_bib19","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1101\/gad.343129.120","article-title":"Senescence and the SASP: many therapeutic avenues","volume":"34","author":"Birch","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.omton.2026.201129_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.semcancer.2021.03.021","article-title":"Biological functions of therapy-induced senescence in cancer","volume":"81","author":"Fitsiou","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omton.2026.201129_bib21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.trecan.2020.05.004","article-title":"Senescent Cells in Cancer Therapy: Friends or Foes?","volume":"6","author":"Wang","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.omton.2026.201129_bib22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/acel.12518","article-title":"Small molecule compounds that induce cellular senescence","volume":"15","author":"Petrova","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.omton.2026.201129_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11190","article-title":"Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL","volume":"7","author":"Yosef","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201129_bib24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/acel.12344","article-title":"The Achilles' heel of senescent cells: from transcriptome to senolytic drugs","volume":"14","author":"Zhu","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.omton.2026.201129_bib25","doi-asserted-by":"crossref","first-page":"12844","DOI":"10.18632\/aging.102557","article-title":"Targeting senescent cells: approaches, opportunities, challenges","volume":"11","author":"von Kobbe","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.omton.2026.201129_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41573-024-01074-4","article-title":"Senescence as a therapeutic target in cancer and age-related diseases","volume":"24","author":"McHugh","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2026.201129_bib27","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1038\/s41467-025-60971-3","article-title":"Cx43 enhances response to BRAF\/MEK inhibitors by reducing DNA repair capacity","volume":"16","author":"Varela-V\u00e1zquez","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201129_bib28","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/s41388-020-1354-9","article-title":"Senescence as a therapeutically relevant response to CDK4\/6 inhibitors","volume":"39","author":"Wagner","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201129_bib29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201129_bib30","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.omton.2026.201129_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2026.201129_bib32","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors' current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2026.201129_bib33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/acel.12445","article-title":"Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors","volume":"15","author":"Zhu","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.omton.2026.201129_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.564108","article-title":"Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent","volume":"11","author":"Mohamad Anuar","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omton.2026.201129_bib35","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1039\/c2ob26398j","article-title":"Synthesis of 4,6-disubstituted 2-(4-morpholinyl)pyrimidines by cross-coupling reactions using triorganoindium compounds","volume":"10","author":"Mart\u00ednez","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.omton.2026.201129_bib36","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1002\/1878-0261.13312","article-title":"Targeting senescence as an anticancer therapy","volume":"16","author":"Bousset","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omton.2026.201129_bib37","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 Inhibition in Cancer: Beyond Cell Cycle Arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omton.2026.201129_bib38","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201129_bib39","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/cr900028p","article-title":"Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer","volume":"109","author":"Parker","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.omton.2026.201129_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010104","article-title":"Recent Advances in Pyrimidine-Based Drugs","volume":"17","author":"Nammalwar","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omton.2026.201129_bib41","doi-asserted-by":"crossref","first-page":"986","DOI":"10.4161\/cbt.7.7.6181","article-title":"Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?","volume":"7","author":"Showalter","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.omton.2026.201129_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1189015","article-title":"Cellular senescence: a double-edged sword in cancer therapy","volume":"13","author":"Xiao","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201129_bib43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","article-title":"Senescence and cancer - role and therapeutic opportunities","volume":"19","author":"Schmitt","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201129_bib44","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","article-title":"Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor","volume":"6","author":"Copp\u00e9","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.omton.2026.201129_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.omton.2026.201129_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13767","article-title":"Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age","volume":"22","author":"Islam","year":"2023","journal-title":"Aging Cell"},{"key":"10.1016\/j.omton.2026.201129_bib47","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cell.2017.05.015","article-title":"Senescence in Health and Disease","volume":"169","author":"He","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201129_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4159013","article-title":"Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy","volume":"2018","author":"Malavolta","year":"2018","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.omton.2026.201129_bib49","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ncb2784","article-title":"A complex secretory program orchestrated by the inflammasome controls paracrine senescence","volume":"15","author":"Acosta","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omton.2026.201129_bib50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41419-022-04569-3","article-title":"Genome wide CRISPR\/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence","volume":"13","author":"Carpintero-Fern\u00e1ndez","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omton.2026.201129_bib51","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41419-022-05089-w","article-title":"Extracellular vesicles enriched in connexin 43 promote a senescent phenotype in bone and synovial cells contributing to osteoarthritis progression","volume":"13","author":"Varela-Eir\u00edn","year":"2022","journal-title":"Cell Death Dis."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:38:07Z","timestamp":1778938687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329926000056"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201129","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyrimidine-based compounds as promising anticancer agents targeting tumor cell senescence","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201129"}}